

2nd CRIG Industrial Partnering Event

25th October 2019 - Auditorium 4, Sint-Denijslaan 485, Ghent (Belgium)

Preliminary program:

8.00-9.00 **Breakfast sessions** – Discussion tables on developments and innovation in

1. Immuno-oncology
2. Clinical trials
3. AI and precision medicine (moderator: Ingrid Mas, Inovigate)
4. Topic of choice (upon registration)

9:00-9:10 **Welcome**

Prof. Jo Vandesompele, UGent, CRIG Chairman

9.10-10:00 **Plenary talk**

Dr. David Gilham, Celyad (*title to be confirmed*)

10:00-10:50 **Parallel sessions 1**

Session 1A “Innovations in cancer therapy: immuno-oncology” (moderated by Hetty Helsmoortel, molecular biologist & science communicator)

- ‘[CAR-T trials at UZ Gent: being a privileged partner of the industry in a novel field](#)’
Prof. Tessa Kerre (U(Z)Gent, CRIG)
- ‘[Challenges and hurdles in CAR-T treatment of children](#)’
Prof. Barbara De Moerloose (U(Z)Gent, CRIG)
- ‘[GMP facility: on site production of immunotherapeutics at UZ Gent](#)’
Prof. Bart Vandekerckhove (U(Z)Gent, CRIG)
- ‘[The CliniMACS Prodigy as platform for centralized CAR-T cell production](#)’
Jordy Blaauwendraad (Miltenyi Biotec)
- Pitch by [Janssen Pharmaceutica](#) (*title to be confirmed*)
Dr. Janine Arts
- ‘[Quality by Design to accelerate T-cell based process development](#)’
Gisèle Deblandre (MaSTherCell)

Session 1B “Innovations in cancer therapy: RNA based therapies, antibody/peptide therapies and cancer vaccines”

- ‘[NESPR and pipeline/screening platform for novel lncRNA abled therapies](#)’
Prof. Pieter Mestdagh (UGent, CRIG)
- ‘[mRNA Galsomes: making mRNA vaccines more effective and controlled](#)’
Dr. Ine Lentacker (UGent, CRIG)
- ‘[Repurposing cationic amphiphiles for improved cellular delivery of RNA therapeutics](#)’
Prof. Koen Raemdonck (UGent, CRIG)
- 1 CRIG pitch
- 2 company pitches

10:50-11:10 **Coffee break & sponsor booths**

11:10-12:00 **Parallel sessions 2:**

Session 2A “Innovations in cancer therapy: immuno-oncology” (moderated by Hetty Helsmoortel – UGent, CRIG)

- ‘Taking dendritic cells to medicine: the MIDRIX platform for vaccination in lung cancer and beyond’
Prof. Karim Vermaelen (U(Z)Gent, CRIG)
- Pitch by AstraZeneca (*title & speaker to be confirmed*)
- ‘Drug targeting to lymphoid tissue’
Prof. Bruno De Geest (UGent, CRIG)
- ‘The BiTE technology’
Amgen (*speaker to be confirmed*)
- 1 CRIG/company pitch on NK therapy
- 1 company pitch

Session 2B “Cancer modelling”

- ‘Dog models of naturally occurring cancer’
Prof. Hilde de Rooster (UGent, CRIG)
- ‘Spontaneous microbiota-driven metastatic CRC mouse model’
Prof. Lars Vereecke (VIB-UGent, CRIG)
- ‘Selecting the right leukemia therapy’
Prof. Steven Goossens (VIB-UGent, CRIG)
- ‘The xenopus platform’
Prof. Kris Vleminckx (UGent, CRIG)
- 1 CRIG pitch
- 1 CRIG/company pitch

12:00-12:50 **Speed dating round** (moderated by Dr. Hetty Helsmoortel (molecular biologist & science communicator, CRIG))

12.50-13.50 **Lunch, partnering discussions & sponsor booths**

13.50-14.40 **Plenary talk**

Prof. Hans Hofstraat, Philips Research (*title to be confirmed*)

14:40-15:30 **Parallel sessions 3**

Session 3A “Precision oncology” (moderated by Hetty Helsmoortel – UGent, CRIG)

- ‘Cancer therapeutics and barrier dysfunction/dysbiosis’
Prof. An Hendrix (UGent, CRIG)
- ‘Combination of immunotherapy and radiotherapy in clinical trials’
Prof. Piet Ost (U(Z)Gent, CRIG)
- ‘Targeted proximity ligation assays & NGS for robust detection of structural variation in fragmented FFPE samples’
Dr. H. Feitsma (Cergentis)



CANCER RESEARCH INSTITUTE GHENT

- ‘OncoLize – Treating tumors from the Inside’
Dr. Mike de Leeuw (OncoLize)
- 1 CRIG pitch
- 1 company pitch

Session 3B “New players in the Belgian ecosystem and spinoff projects in oncology” (moderated by dr. Daisy Flamez - UGent, CRIG)

- ‘Cancer-T in motion, a novel platform for informing patients through digital tools’
Prof. Tessa Kerre (U(Z)Gent, CRIG)
- ‘CRIG as beta user: Trince’
Dr. Stephan Stremersch, Prof. Kevin Braeckmans (UGent, CRIG)
- ‘OhmX.Bio and NXTGNT’
Prof. Gerben Menschaert
- ‘Gulliver BioMed’
Prof. Jan Gettemans
- 2 pitches

15:30-15:50 **Coffee break & sponsor booths**

15:50-16:50 **Parallel sessions 4:**

Session 4A: “Platforms and technologies in (non-invasive) diagnostics” (moderated by dr. Hetty Helsmoortel – UGent, CRIG)

- ‘New alphabodies platform validation’
Prof. Pieter Van Vlierberghe (UGent, CRIG)
- Pitch by *Stilla Technologies* (speaker & title to be confirmed)
- ‘High throughput immunoprofiling for cancer diagnostics’
Christof Neuman (IPDx)
- ‘Methylation cell free DNA’
Prof. K. De Preter (U(Z)Gent, CRIG)
- ‘Molecular diagnostic platform’
J. Van der Meulen (U(Z)Gent, CRIG)
- ‘Cell by Design® (CbD), a cloud-based software platform that facilitates scalable, cost effective and sustainable ATMP process development’
Dominiek Rossillion (QBD) & Evan Claes (Antleron)
- 1 CRIG pitch

Session 4B “AI, digital health, Big Data” (moderated by dr. Ingrid Maes - Inovigate)

- ‘The Universal Digital Health Platform initiative, a patient data-centric digital health solution connecting industry, HCPs and patients to deliver personalised and cost-efficient outcomes’
Dr. Ingrid Maes (Inovigate)
- ‘Deep Learning for metastasis detection in lymph nodes, and others’
Nicolas Deruytter (ML6)
- ‘Biocartis - Idylla™ – the art of intelligence inside a box’
Dr. Bram De Craene (Biocartis)



CANCER RESEARCH INSTITUTE GHENT

- 'Big single-cell data science for cancer application'
Prof. Yvan Saeys (VIB-UGent, CRIG)
- 2 CRIG pitches
- 1 company pitch

16.50-17:00 **Summary & closing remarks**

17.00-18.00 **Networking reception & partnering discussions**

Thanks to our sponsors!

Gold sponsors



Silver sponsors





CANCER RESEARCH INSTITUTE GHENT

Bronze sponsors

